Universität zu Köln

Gschwend, J. E., Albers, P., Boegemann, M., Goebell, P., Heidenreich, A., Klier, J., Koenig, F., Machtens, S., Pantel, K. and Thomas, C. (2018). Metastatic castration-resistant prostate cancer. Use of cabazitaxel taking into consideration current data. Urologe, 57 (1). S. 34 - 40. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0563

Full text not available from this repository.

Abstract

Background. At the 2016 ASCO annual meeting, new data from two randomized phase III studies concerning taxane-based chemotherapy as a treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC) were presented. Objectives. The focus is on the clinical impact of these data. Materials andmethods. A group of German experts in the field of urogenital-oncologic expertise discussed the clinical impact with respect to the current data. Results. The study results support the current clinical data. They confirm the efficacy and safety of cabazitaxel beyond first-line therapy with docetaxel for patients withmCRPC. Conclusions. Cabazitaxel is an important treatment option after docetaxel progression. With respect to the performance status of a patient, it is adequate to reduce the dosage to 20mg/m(2) cabazitaxel.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Gschwend, J. E. UNSPECIFIED UNSPECIFIED UNSPECIFIED Albers, P. UNSPECIFIED UNSPECIFIED UNSPECIFIED Boegemann, M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Goebell, P. UNSPECIFIED UNSPECIFIED UNSPECIFIED Heidenreich, A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Klier, J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Koenig, F. UNSPECIFIED UNSPECIFIED UNSPECIFIED Machtens, S. UNSPECIFIED UNSPECIFIED UNSPECIFIED Pantel, K. UNSPECIFIED UNSPECIFIED UNSPECIFIED Thomas, C. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-204404
DOI:	10.1007/s00120-017-0533-y
Journal or Publication Title:	Urologe
Volume:	57
Number:	1
Page Range:	S. 34 - 40
Date:	2018
Publisher:	SPRINGER HEIDELBERG
Place of Publication:	HEIDELBERG
ISSN:	1433-0563
Language:	German
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language MITOXANTRONE PLUS PREDNISONE; PHASE-III TRIAL; SURVIVAL; DOCETAXEL; ABIRATERONE; MCRPC Multiple languages Urology & Nephrology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/20440